Navigation Links
Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference
Date:7/9/2010

LAIYANG, China, July 9 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (Nasdaq: JGBO) (the "Company" or "Jiangbo"), today announced that its management will present at the Global Hunter Securities China Investment Conference, which takes place July 11-13, 2010 at the St. Regis Hotel in San Francisco.

Presentation Time: 7:30 a.m. PT, Monday, July 12, 2010

Location: Presentation Room 2, St. Regis Hotel, San Francisco

This event features approximately 100 China-based companies, most of which have shares that trade on U.S. exchanges. Companies from various sectors will make presentations to institutional investors during the conference, which serves as a forum for management teams to showcase their investment rationales, growth plans, current outlooks and positioning in China's growing marketplace. For more information about the conference and registration, please visit http://www.ghsecurities.com .

About Global Hunter Securities

Global Hunter Securities, LLC is a full service investment bank focusing on middle market corporate and institutional clients around the world. The firm provides insightful research, innovative capital raising and financial advisory and restructuring services supported by a sales and trading staff with world-wide reach. Global Hunter has offices in San Francisco, Los Angeles, New York, Houston, New Orleans, Newport Beach and Hong Kong, as well as a strong presence and reputation in mainland China. For more information about Global Hunter, please visit http://www.ghsecurities.com .

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website ( http://www.jiangbopharma.com ).

    For more information, please contact:

    Jiangbo Pharmaceuticals, Inc.
     Ms. Elsa Sung, CFO
     Tel:   +1-954-903-9378 x2
     Email: elsasung@jiangbo.com
     Web:   http:// www.jiangbopharma.com

    CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com


'/>"/>
SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer
2. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
3. Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010
4. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
5. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
6. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
7. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
8. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
9. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
10. ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc.
11. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... India , December 7, 2016 According to ... (Services, Software), Delivery Mode, Product Type (Integrated, Standalone), Model (Knowledge-Based), Type (Therapeutic, ... MarketsandMarkets, The CDSS Market is expected to reach USD 1,519.2 Million by ... Continue Reading ... ...
(Date:12/7/2016)... , Dec. 7,2016  Based on ... delivery industry, Frost & Sullivan recognizes Nemaura ... & Sullivan Award for Enabling Technology Leadership. ... the loopholes in traditional drug delivery technologies, ... liquid microneedle-based drug delivery technologies, Memspatch and ...
(Date:12/7/2016)... Inc. (NASDAQ: IONS ), the leader in antisense therapeutics, ... BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, December ... A live webcast of the presentation will be available on the ... be available within 48 hours and will be archived for a ... , , ...
Breaking Medicine Technology:
(Date:12/7/2016)... Ill. (PRWEB) , ... December 07, 2016 , ... Levels ... early-stage brain damage, according to a study appearing online in the journal Radiology. , ... is expected to increase significantly due to the rapidly aging population. Damage to both ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... is now promoting to the US market its advanced highly customizable contact technology ... and ODU TURNTAC®. These advanced technologies are ideal for a wide range of ...
(Date:12/7/2016)... TX (PRWEB) , ... December 07, 2016 , ... ... offering insurance and financial planning services to families and business owners in the ... funds on behalf of the Dallas Fallen Officer Foundation. , Established in 2009 ...
(Date:12/7/2016)... ... , ... A. Kevin Spann Insurance, a New York-based firm offering insurance and ... a charity drive to raise funds that will benefit the Marine Corps League. , ... Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin Spann team plans ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... to announce that its fully redesigned website, which launched October 17, 2016, features ... sleek responsive design and easy-to-navigate layout. Visitors and patients can discover the latest ...
Breaking Medicine News(10 mins):